These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 16341288)

  • 21. An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.
    Crasto W; Khunti K; Davies MJ
    Drugs Today (Barc); 2011 Nov; 47(11):839-56. PubMed ID: 22146227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exenatide: from the Gila monster to the pharmacy.
    Triplitt C; Chiquette E
    J Am Pharm Assoc (2003); 2006; 46(1):44-52; quiz 53-5. PubMed ID: 16529340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.
    Meier JJ
    Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
    Molina Vega M; Muñoz-Garach A; Tinahones FJ
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):207-217. PubMed ID: 29260924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exenatide and weight loss.
    Bradley DP; Kulstad R; Schoeller DA
    Nutrition; 2010 Mar; 26(3):243-9. PubMed ID: 20152707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A; Brønden A; Knop FK
    Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
    Ghazi T; Rink L; Sherr JL; Herold KC
    Diabetes Care; 2014; 37(1):210-6. PubMed ID: 23939544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
    Kolterman OG; Kim DD; Shen L; Ruggles JA; Nielsen LL; Fineman MS; Baron AD
    Am J Health Syst Pharm; 2005 Jan; 62(2):173-81. PubMed ID: 15700891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exenatide: a review from pharmacology to clinical practice.
    Gentilella R; Bianchi C; Rossi A; Rotella CM
    Diabetes Obes Metab; 2009 Jun; 11(6):544-56. PubMed ID: 19383034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exenatide: incretin therapy for patients with Type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Expert Rev Endocrinol Metab; 2008 Nov; 3(6):671-690. PubMed ID: 30764058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretins and their role in the management of diabetes.
    Frias JP; Edelman SV
    Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exenatide.
    Keating GM
    Drugs; 2005; 65(12):1681-92; discussion 1693-5. PubMed ID: 16060703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
    Linnebjerg H; Park S; Kothare PA; Trautmann ME; Mace K; Fineman M; Wilding I; Nauck M; Horowitz M
    Regul Pept; 2008 Nov; 151(1-3):123-9. PubMed ID: 18675854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is exenatide a useful addition to diabetes therapy?
    Mikhail NE
    Endocr Pract; 2006; 12(3):307-14. PubMed ID: 16772206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.